正在加载视频...
视频加载失败
Update from ESGO 2026 PYNNACLE Phase 2 study: Interim results from the ovarian cancer cohort Evaluating a first-in-class p53 reactivator, rezatapopt*, in TP53 Y220C–mutant advanced solid tumours 📺 Clinical insights and expert discussion from Profs Domenica Lorusso and Jean-Sebastien Frenel This programme has been sponsored by PMV Pharma and... show more
0 条评论
暂无评论
原始帖子的评论将显示在这里
